Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of inflammatory and structural joint damage in psoriasis and psoriatic arthritis treated with secukinumab
2014-004798-17Phase 2Completed
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of secukinumab in psoriasis and psoriatic arthritis (PsA), sponsored by Universitätsklinikum Erlangen. Primary endpoint: Change in PsAMRIS score. Started Mar 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2014-004798-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004798-17.